BioKier

Focus: BioKier is a biotechnology company focused on metabolic diseases, particularly diabetes and related conditions, based in Raleigh, NC. Company scale and stage remain undisclosed.

Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About BioKier

AI assessmentNot Hiring

No open roles listed right now. Follow BioKier to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BKR-017

Type 2 Diabetes

N/A

Clinical Trials (1)

NCT04673656Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients

N/A

Help build intelligence for BioKier

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage focus on high-prevalence metabolic diseases (Type 1 and Type 2 diabetes, hypercholesterolemia) with significant market opportunity
Active pipeline with multiple indications for lead program BKR-017 across diabetes spectrum suggests broad therapeutic potential
Ground-floor opportunity at pre-revenue stage with opportunity to shape company culture and scientific direction

Watch Out For

No active job openings reported, suggesting limited near-term hiring or possible transition phase
Pre-revenue stage with undisclosed funding and employee count creates visibility gaps on financial runway and organizational stability
Only Phase 1/2 stage programs with no Phase 3 data or approved products means 5+ years minimum to potential revenue inflection

Generated by Claude from BioKier's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

BKR-017

Type 2 Diabetes

N/A

Clinical Trials (1)

NCT04279444Effects of BKR-017 on Insulin Resistance in Type 2 Diabetes Patients

N/A

BKR-017

Hypercholesterolemia

N/A

Clinical Trials (1)

NCT06556745Pharmacokinetics of Butyrate Tablet BKR-017

N/A